Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testing

用于药物和毒理学测试的 96 孔 3D 皮肤模型的新颖制造和商业化

• 批准号: 103597
• 金额: $ 25.99万
• 依托单位: ALCYOMICS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103597
• 关键词: Novel; manufacture; commercialisation; 96; well

Alcyomics have developed unique, non-animal, non-artificial human skin explant assays (Skimune™ and Skimune™3D) which can test for safety and efficacy of novel drugs and compounds, including cosmetics. Alcyomics assays enable the products of the pharmacuetical, chemical and cosmetics industries to reach the clinic and/or the market place, quicker by early assessment of their safety profiles. Alcyomics has recently improved their service offering by developing Skimune™ 3D, a new 3D human skin model for skin sensitisation which predicts adverse immune responses or allergy, as well as toxic profiles, of the compounds under test. The next stage of development involves improving the scalablility of this 3D skin model to increase capacity and further commercialisation. The project funding will be used to transform the existing model into a standard 96-well plate format, thereby increasing the number of drugs and novel compounds that can be tested and creating a platform that is amenable to future automation. The construction of this tool will involve novel, bespoke manufacturing processes and collaboration with another North East company (ReproCELL). Successful completion of this work will enable Alcyomics to increase the capacity of their drug testing operation for the toxicology and genotoxicity markets. This will provide a greater service provision and aid Alcyomics to achieve its objective to become a 'one-stop shop' for safety and efficacy profiling for the pharmaceutical, chemical and cosmetics industry globally. ReproCELL as distributor will also aid in increasing sales and marketing.

Alcyomics已经开发出独特的、非动物、非人工的人类皮肤外植体检测（Skimune™和Skimune™3D），可以测试新药和化合物（包括化妆品）的安全性和有效性。Alcyomics分析使制药、化工和化妆品行业的产品能够通过对其安全性的早期评估更快地进入临床和/或市场。Alcyomics最近通过开发Skimune™3D改进了他们的服务，这是一种新的3D人体皮肤模型，用于皮肤致敏，预测不良免疫反应或过敏，以及测试化合物的毒性谱。下一阶段的开发包括提高这种3D皮肤模型的可扩展性，以增加容量和进一步的商业化。项目资金将用于将现有模型转换为标准的96孔板格式，从而增加可测试的药物和新化合物的数量，并创建一个适合未来自动化的平台。该工具的构建将涉及新颖的定制制造流程，并与另一家东北公司（ReproCELL）合作。这项工作的成功完成将使Alcyomics能够提高其毒理学和遗传毒性市场的药物测试业务的能力。这将提供更大的服务，并帮助Alcyomics实现其目标，即成为全球制药、化学和化妆品行业安全性和有效性分析的“一站式商店”。ReproCELL作为分销商也将有助于增加销售和营销。